Integrating molecular profiling, histological type and other variables: Defining the fingerprint of responsiveness to treatment

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Viale, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast carcinoma; Gene expression profiling; Immunohistochemistry; Predictive markers; Prognostic markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 71849094765     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70269-3     Document Type: Article

References (27)

1. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 (2006) 2137-2150
2. Sotiriou C., and Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 360 (2009) 790-800
3. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumour markrs in breast cancer. J Clin Oncol 25 (2007) 5287-5312
4. Goldhirsch A., Wood W.C., Gelber R.D., et al. Progress and promise: highlights of the International Expert Consensus on the Primary Therapy of Early Breast Cancer 2007. Ann Oncol 18 (2007) 1133-1144
5. van't Veer L.J., Dai H., van de Vijver M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
6. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
7. van de Vijver M., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
8. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
9. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?. Genet Med 11 (2009) 66-73
10. Ibrahim M., Dodson A., Barnett S., Fish D., Jasani B., and Miller K. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am J Clin Pathol 129 (2008) 398-409
11. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 25 (2007) 118-145
12. Paik S., Shak S., Tang G., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
13. Miller W.R., Larionov A., Renshaw L., et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to Letrozole. J Clin Oncol (2009) in press
14. Dowsett M., and Dunbier A.K. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14 (2008) 8019-8026
15. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
16. Weigelt B., Horlings H.M., Kreike B., et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216 (2008) 141-150
17. Bidard F.C., Conforti R., Boulet T., Michiels S., Delaloge S., and André F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohisto-chemical analysis based on 143 "triple-negative" breast cancers. Ann Oncol 18 (2007) 1285-1286
18. Hugh J., Hanson J., Cheang M., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27 (2009) 1168-1176
19. Ayers M., Symmans W.F., Stec J., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 (2004) 2284-2293
20. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Human Cancer Biol 11 (2005) 732-740
21. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 24 (2006) 4236-4244
22. Flanagan M.B., Dabbs D.J., Brufsky A.M., Beriwal S., and Bhargava R. Histopathologic variables predict Oncotype DX™ recurrence score. Mod Pathol 21 (2008) 1255-1261
23. Jiminez R.E., Wallis T., and Visscher D.W. Centrally necrotizing carcinomas of the breast. A distinct histologic subtype with aggressive clinical behavior. Am J Surg Path 25 (2001) 331-337
24. Maiorano E, Regan MM, Viale G, et al. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer. Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat 2009, in press.
25. Viale G., Regan M.M., Mastropasqua M.G., et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100 (2008) 207-212
26. Viale G., Giobbie-Hurder A., Regan M.M., et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1-98 comparing adjuvant Tamoxifen with Letrozole. J Clin Oncol 26 (2008) 5569-5575
27. Parker J.S., Mullins M., Cheang M., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27 (2009) 1160-1167